STARR Trans-anal Resection Versus Vaginal Rectocele Repair Using Elevate: Effects on Defecatory Function (RectoVerso)

October 30, 2015 updated by: Centre Hospitalier Universitaire de Nīmes

STARR Type Trans-anal Resection Versus Vaginal Rectocele Repair Using a Posterier Elevate Prothesis: a Randomized, Multicentric, Prospective Study on Defecatory Function

The primary objective of this study is to compare the function results between two methods for surgically repairing rectoceles: vaginal versus endo-anal surgery. Our working hypothesis is that the relatively new type of endo-anal surgery will result in better voiding function compared to the traditional vaginal surgery.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
4

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Marseille, France
        • Hopital de la Conception
      • Montpellier, France
        • Clinique Beau Soleil
      • Strasbourg, France
        • Clinique Adassa
      • Toulouse, France
        • Hôpital Paule de Viguier, CHU de Toulouse
      • Toulouse, France
        • Hôpital Purpan, CHU de Toulouse
    • Gard
      • Nîmes, Gard, France, 30029
        • Centre Hospitalier Universitaire de Nîmes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • patient is not under any type of guardianship
  • patient has a rectocele > 3 cm during defecography
  • patient has persistent defecatory troubles depite medical treatment (laxatives for at least 1 month) and an ODS score > 10
  • patient recieved information and signed the consent form

Exclusion Criteria:

  • patient cannot read French
  • patient has an asymptomatic rectocele
  • patient with an enterocele at rest upon defecography, with opacification of the small bowel
  • patient with non-rehabilitated anorectal asynchrony (anism)
  • patient with anal incontinence, Wexner score > 7
  • patient has a rectal lesion
  • patient has previously had rectal surgery including a colorectal anastomosis
  • patient has previously had a surgery involving disection of the rectovaginal wall, except for myorraphy of relever muscles
  • patient has previously had pelvic radiotherapy
  • anal sphincter insufficiency detected by rectomanometry
  • megarectum detected by rectomanometry and defecography
  • granule transit anomaly: > 70h
  • exteriorized rectal prolapse
  • rectovaginal fistule
  • intestinal inflammatory disease
  • anal stenosis
  • anal or rectal tumor
  • patient refuses to participate or refuses to sign consent
  • patient is enrolled in another study
  • contra indication for general or localized anesthesia
  • patient does not have social security coverage

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: STARR arm
In this group of patients, the STARR transanal stapling system is used to treat the rectocele.
Procedure: STARR rectocele repair
The STARR transanal stapling system is used to repair a rectocele.
Active Comparator: Elevate arm
In this group of patients, a posterior Elevate mesh is placed transvaginally to treat the rectocele.
Procedure: Elevate mesh rectocele repair
A posterior Elevate mesh is placed transvaginally to repair a rectocele.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
presence/absence of a 50% drop in the ODS score
Time Frame: 12 months
presence/absence of a 50% drop in the ODS score: constipation score defined by Altomare et al, 2008.
12 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
presence/absence of prolapse recurrence
Time Frame: 6 weeks
presence/absence of prolapse recurrence: determined by prolapse staging
6 weeks
Frequency of laxative use
Time Frame: 6 weeks
6 weeks
Intervention time (min)
Time Frame: 1 day
1 day
Questionnaire PFDI 20
Time Frame: 6 weeks
6 weeks
Questionnaire PFIQ 7
Time Frame: 6 weeks
6 weeks
Questionnaire SF 36
Time Frame: 6 weeks
6 weeks
Questionnaire PISQ-12
Time Frame: 6 weeks
6 weeks
presence/absence of prolapse recurrence
Time Frame: 6 months
presence/absence of prolapse recurrence: determined by prolapse staging
6 months
presence/absence of prolapse recurrence
Time Frame: 12 months
presence/absence of prolapse recurrence: determined by prolapse staging
12 months
presence/absence of prolapse recurrence
Time Frame: 36 months
presence/absence of prolapse recurrence: determined by prolapse staging
36 months
Frequency of laxative use
Time Frame: 6 months
6 months
Frequency of laxative use
Time Frame: 12 months
12 months
Frequency of laxative use
Time Frame: 36 months
36 months
Questionnaire PFDI 20
Time Frame: 6 months
6 months
Questionnaire PFDI 20
Time Frame: 12 months
12 months
Questionnaire PFDI 20
Time Frame: 36 months
36 months
Questionnaire PFIQ 7
Time Frame: 6 months
6 months
Questionnaire PFIQ 7
Time Frame: 12 months
12 months
Questionnaire PFIQ 7
Time Frame: 36 months
36 months
Questionnaire SF 36
Time Frame: 6 months
6 months
Questionnaire SF 36
Time Frame: 12 months
12 months
Questionnaire SF 36
Time Frame: 36 months
36 months
Questionnaire PISQ-12
Time Frame: 6 months
6 months
Questionnaire PISQ-12
Time Frame: 12 months
12 months
Questionnaire PISQ-12
Time Frame: 36 months
36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Hospitalier Universitaire de Nīmes

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Renaud de Tayrac, MD PhD, Centre Hospitalier Universitaire de Nîmes

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2011

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2015

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2015

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 9, 2010

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 9, 2010

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 10, 2010

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 1, 2015

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 30, 2015

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • PHRC-I/2010/RdeT-01
  • 2010-A00665-34 (Other Identifier: Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps))

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings